PENNINGTON, N.J. and SAN DIEGO, Nov. 30, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient's own immune system to target and eradicate cancer, today announced the pricing of its "reasonable best efforts" public offering of 1,166,667 shares of common stock (or common stock equivalents) and Common Warrants to purchase 1,166,667 shares of common stock at a combined price of $3.00 per share, for aggregate gross proceeds of $3.5 million, before deducting placement agent fees and other offering expenses.
Read more at prnewswire.comOncoSec Announces Pricing of $3.5 Million Public Offering
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Microsoft%20Corporation%20logo%20on%20sign-by%20Jean-Luc%20Ichard%20via%20iStock.jpg)
/The%20sign%20for%20Marvell%20Technology%20out%20front%20of%20a%20corporate%20office%20by%20Valeriya%20Zankovych%20via%20Shutterstock.jpg)
